1. Home
  2. NRIX vs HLF Comparison

NRIX vs HLF Comparison

Compare NRIX & HLF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NRIX
  • HLF
  • Stock Information
  • Founded
  • NRIX 2009
  • HLF 1980
  • Country
  • NRIX United States
  • HLF United States
  • Employees
  • NRIX N/A
  • HLF N/A
  • Industry
  • NRIX Biotechnology: Pharmaceutical Preparations
  • HLF Other Pharmaceuticals
  • Sector
  • NRIX Health Care
  • HLF Health Care
  • Exchange
  • NRIX Nasdaq
  • HLF Nasdaq
  • Market Cap
  • NRIX 750.4M
  • HLF 877.4M
  • IPO Year
  • NRIX 2020
  • HLF N/A
  • Fundamental
  • Price
  • NRIX $12.00
  • HLF $8.23
  • Analyst Decision
  • NRIX Strong Buy
  • HLF Strong Buy
  • Analyst Count
  • NRIX 14
  • HLF 4
  • Target Price
  • NRIX $26.64
  • HLF $11.50
  • AVG Volume (30 Days)
  • NRIX 1.7M
  • HLF 1.2M
  • Earning Date
  • NRIX 10-09-2025
  • HLF 11-05-2025
  • Dividend Yield
  • NRIX N/A
  • HLF N/A
  • EPS Growth
  • NRIX N/A
  • HLF 285.96
  • EPS
  • NRIX N/A
  • HLF 3.17
  • Revenue
  • NRIX $83,687,000.00
  • HLF $4,928,500,000.00
  • Revenue This Year
  • NRIX $58.48
  • HLF $1.02
  • Revenue Next Year
  • NRIX N/A
  • HLF $4.52
  • P/E Ratio
  • NRIX N/A
  • HLF $2.59
  • Revenue Growth
  • NRIX 48.32
  • HLF N/A
  • 52 Week Low
  • NRIX $8.18
  • HLF $5.04
  • 52 Week High
  • NRIX $29.56
  • HLF $10.83
  • Technical
  • Relative Strength Index (RSI)
  • NRIX 66.65
  • HLF 36.22
  • Support Level
  • NRIX $10.28
  • HLF $8.50
  • Resistance Level
  • NRIX $11.70
  • HLF $8.89
  • Average True Range (ATR)
  • NRIX 0.79
  • HLF 0.31
  • MACD
  • NRIX 0.24
  • HLF -0.04
  • Stochastic Oscillator
  • NRIX 98.06
  • HLF 7.99

About NRIX Nurix Therapeutics Inc. Common stock

Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.

About HLF Herbalife Ltd.

Herbalife Ltd is an international nutrition company that provides health and wellness products to consumers in 95 markets, which consist of countries and territories, through their direct-selling business model. Companies' products are weight management, targeted nutrition, Energy, Sports and Fitness, Outer Nutrition and Literature, Promotional, and Other. Weight management generates the majority of revenue from products like Meal replacements, protein shakes, drink mixes, weight loss enhancers, and healthy snacks. Geographically, the main segments are North America, Latin America, EMEA, Asia Pacific regions, and China.

Share on Social Networks: